Brief: Cellares Says Co, Lyell To Evaluate Automated Manufacturing Of Lyell's Car T-Cell Therapy On Cellares' Cell Shuttle Platform
11/09/2023 14:50
Sept 11 (Reuters) - Lyell Immunopharma Inc LYEL.O :
* CELLARES - CO, LYELL TO EVALUATE AUTOMATED MANUFACTURING
OF
LYELL'S CAR T-CELL THERAPY ON CELLARES' CELL SHUTTLE PLATFORM
Source text for Eikon: ID:nPn344L0xa
Further company coverage: LYEL.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Lyell Immunopharma
See all newsBrief: Lyell Immunopharma Says Additional Clinical Data And End-Of-Phase 1 FDA Meeting Expected In 2027
Lyell Immunopharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Lyell Immunopharma, Inc. expected to post a loss of $2.08 a share - Earnings Preview
Brief: Lyell Immunopharma Q2 Operating Expenses USD 47.341 Million
Brief: Lyell Immunopharma Shows Updated Safety Data For Ronde-Cel In Patients With Large B-Cell Lymphoma